TORONTO, ON / ACCESSWIRE / May 31, 2016 / Fountain Asset Corp. (TSXV: FA) (“Fountain Asset”) announces its financial results for the first quarter ending March 31, 2016.

Highlights

• Three month revenue of $0.3 million compared to $0.4 million in 2015;
• Break-even first quarter compared to net income of $0.1 million in 2015;
• Portfolio of publicly traded companies increased to $5.5 million compared to $5.2 million at year end;
• Total assets of $12.9 million at the end of the quarter.

Management’s First Quarter Comments

For the quarter ended March 31, 2016, the Company reported net income of $17,561, or $0.00 per share compared to a net income of $190,555, or $0.00 per share in the prior year. Total assets as at March 31, 2016 were $12.9 million compared to $12.9 million as at December 31, 2015. The Company’s portfolio of public companies increased to $5.5 million at quarter end compared to $5.2 million at year end.

“Within the quarter we saw our portfolio of public companies make a positive rebound from the end of 2015. We continue to be excited about the prospects for our public company portfolio and our roster of private investee companies continue to provide steady monthly cash flows for Fountain,” said Jason Ewart, CEO of Fountain.

A full set of unaudited financial statements and related notes have been filed on SEDAR.

About Fountain Asset Corp.

Fountain Asset Corp. is a merchant bank which provides equity financing, bridge loan services (asset back/collateralized financing) and strategic financial consulting services to companies across many industries such as oil & gas, mining, real estate, manufacturing, retail, financial services, technology and biotechnology. For further information, please contact Jason G. Ewart at (416) 488-7760 or visit Fountain Asset Corp.’s website at www.fountainassetcorp.com.

Forward-Looking Information

These materials include certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Other than statement of historical fact, all statements in this material, including, without limitation, statements regarding fair values of marketable securities, investments, bridge loans, convertible debentures, estimated asset retirement obligations, and future plans and objectives of the Company, are forward-looking statements that involve various known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of these materials. Important factors that could cause actual results to differ materially from the Company’s expectations include, without limitation, the level of bridge loans completed, the nature and credit quality of the collateral security, the sufficiency of cost estimates for remaining reclamation obligations as well as those factors discussed in the Company’s documents filed from time to time with the TSX Venture Exchange, Canadian securities regulators and other regulatory authorities. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Fountain Asset Corp.

ReleaseID: 440596

LOS ANGELES, CA / ACCESSWIRE / May 31, 2016 / iAnthus Capital Management, a company providing financing and managing solutions for licensed cannabis companies throughout the United States, today announced that it will be presenting at the 6th Annual LD Micro Invitational on Tuesday, June 7, 2016 at 2 PM PST / 5 PM EST. Hadley Ford, co-founder and CEO of iAnthus will be giving the presentation and meeting with investors.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

Profiles powered by LD Micro – News Compliments of Accesswire

About iAnthus Capital Management

iAnthus delivers a comprehensive solution for financing and managing licensed cannabis cultivators, processors and dispensaries throughout the United States. Founded by entrepreneurs with decades of experience in investment banking, corporate finance, law and healthcare services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. The Company harnesses these skills to support a diversified portfolio of cannabis industry investments for our shareholders, including direct equity investments in for-profit license holders and lending facilities coupled with management services to not-for-profit license holders. For more information, visit www.ianthuscapital.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Alfia Muzio
Phone: 212-476-2556
Address: 420 Lexington Avenue
Suite 300
New York, NY 10170
Email: alfia.muzio@ianthuscapital.com

SOURCE: iAnthus Capital Management via LD Micro

ReleaseID: 440591

TORONTO, ON / ACCESSWIRE / May 31, 2016 / CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, today announced that it has entered into a sales and ECG services agreement with California-based Vascular Innovations Ltd. (“Vascular Innovations”), to provide post-market surveillance of patients with coronary artery disease treated with a new drug eluting stent (“DES”). The program will first be launched in India through Vascular Concepts Ltd. (“VCL”), an India-based affiliate of Vascular Innovations.

The arrhythmia surveillance deal provides a significant revenue opportunity to CardioComm Solutions which will be supported from the over 250,000 pre-paid ECG reading fees that will follow the purchase of a minimum of 8,250 HeartCheck™ devices. Additional revenue is expected from continued patient use of the HeartCheck™ SMART Monitoring service following completion of a pre-paid one month surveillance period.

Under the six-year renewable agreement, Vascular Innovations will develop sales and marketing channels to hospitals in India for their coronary and structural heart medical devices with post-market surveillance of patients conducted through the use of HeartCheck™ based technologies. The Company confirms that the Vascular Innovations deal was finalized with the placement of an initial order of 250 HeartCheck™ ECG devices. The first phase for launch of the DES in India will require a maximum of 33 months during which period an additional 2,000 HeartCheck™ devices with pre-paid ECG triages will be utilized. Over the next three years a minimum of 6,000 additional HeartCheck™ ECG devices will be purchased with pre-paid ECG triages. Based on the results of their DES treatment program in India, Vascular Innovations plans to expand the launch of their surgical treatments and patient surveillance program into other territories globally from which CardioComm Solutions will derive further benefits.

Under the sponsored arrhythmia/rhythm surveillance program, patients implanted with a Vascular Innovations medical device will be provided a free HeartCheck™ ECG PEN and a pre-paid one month post-surgery arrhythmia/rhythm surveillance service at hospital discharge. Each HeartCheck™ device serial number will be associated with a specific patient and a set number of pre-paid ECG triages that patients will utilize over their first month of recovery. ECG recordings will be taken once each day or if/when a patient feels symptomatic. Patients will utilize the Company’s free GEMS™ Home software to upload recorded ECGs to the Company’s SMART Monitoring ECG service. A triage report will be generated from each uploaded ECG and should an actionable arrhythmia such as atrial fibrillation (“AF”) be found, the patient’s health care provider will be alerted to provide any needed follow up support. After the initial one month period of free arrhythmia surveillance is completed patients will be allowed to keep their HeartCheck™ ECG PENs. The configuration of the 8,250 HeartCheck™ devices will be automatically converted to a per ECG based, pay-for-use-service model and patients may then continue to access the SMART Monitoring ECG service on a per-ECG fee model identical to what is currently offered to the direct to consumer markets globally.

A representative from Vascular Innovations confirmed that an initial market evaluation of the HeartCheck™ technologies has been completed and that eighteen medical centers within India are ready to implement the HeartCheck™ post-surgery arrhythmia surveillance program. Vascular Concepts further confirms that use of their DES implantable devices and an expected atrial occluder for AF treatment will be expanded globally and that use of the HeartCheck™ ECG technologies will increase proportionately.

This is the second Company announcement regarding a partnership agreement to provide services within India, a country which holds significant growth potential for the SMART Monitoring service. This initiative will assist the Company to expand into new markets and provides the first opportunity for CardioComm Solutions’ technologies to be integrated into a patient care management strategy.

To learn more about CardioComm Solutions’ products please see the Company’s websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.

About Vascular Innovations Inc.

Vascular Innovations, Inc. is a premier intellectual property development group providing opportunities for acquisition, merger, or alliances with the latest medical device technologies. Vascular Innovations has assembled a portfolio of technologies from many years of medical device experience. Programs are in many stages, from business plans to pending/issued patent, to stock products ready for market introduction. Innovative technologies are available from the areas of vascular and cardiovascular.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: CardioComm Solutions, Inc.

ReleaseID: 440592

NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of NewLink Genetics Corporation (“NewLink”) (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016.

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired NewLink securities between September 17, 2013 and May 9, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/newlink-genetics-corporation.

The complaint alleges that NewLink continuously touted the effectiveness and favorable safety profile of the company’s lead product candidate, algenpantucel-L, an immunotherapeutic pancreatic cancer treatment. As a result of such public statements, the stock price traded at artificially high levels throughout the class period.

On May 9, 2016, NewLink announced that algenpantucel-L did not achieve its primary endpoint. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink’s Phase 3 Clinical Trial, compared to median survival of 30.4 months for patients treated with standard therapy. Following this news, shares of NewLink were down more than 30% during intraday trading May 10, 2016.

If you suffered a loss in NewLink you have until July 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/newlink-genetics-corporation.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440589

IRVINE, CA / ACCESSWIRE / May 31, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Platform Specialty Products Corporation (“Platform Specialty” or the “Company”) (NYSE: PAH). Investors who purchased or otherwise acquired shares between February 17, 2015 and March 14, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the June 1, 2016, lead plaintiff motion deadline.

If you purchased shares of Platform Specialty during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company failed to disclose that: (1) Arysta had made improper third-party payments in West Africa; and (2) that the foregoing payments were unlawful under the U.S. Foreign Corrupt Practices Act (“FCPA”). On March 11, 2016, the Company revealed in its 2015 annual report that it had “discovered certain payments made to third-party agents in connection with Arysta’s government tender business in West Africa which may be illegal or otherwise inappropriate.”

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 440590

Reduce the High Costs of Printing: A New, Innovative Solution That Allows Companies to Save Toner and Ink and Optimize Their Print Processes

SUWANNEE, GA / ACCESSWIRE / May 31, 2016 / DocPath® TonerMIST(TM) offers the most logical and efficient way to reduce the high costs of printing: a new, innovative solution that allows companies to save toner and ink and optimize their print processes.

DocPath, a leading document software provider, has recently announced the launch of DocPath TonerMIST, one of the company’s latest solutions geared towards providing any type of organization the opportunity to drastically reduce their substantial amount of toner and ink consumption and effectively increase the levels of efficiency, productivity and performance of their print processes.

DocPath TonerMIST features cover two areas; ink and toner saving and efficient remote printing. DocPath’s latest document software allows companies, among other characteristics, to implement a corporate ink and toner saving policy with centralized control settings and apply customized print and saving settings by department or user profile. Likewise, the entire process is completely transparent, meaning that the end user prints as normal without any need of receiving extra training or accessing the intuitive TonerMIST configuration tool.

In addition to considerable toner and ink cost savings, companies also obtain an important decrease in bandwidth consumption, while print files are transmitted more rapidly across their geographically dispersed offices. DocPath’s TonerMIST solution covers these key aspects of the print process by optimizing and compressing print files without affecting the original quality of the file contents.

In conclusion, DocPath TonerMIST is a flexible, non-intrusive toner and ink saving document software that is compatible with any printer type and file format and can by easily integrated into any organization´s infrastructure.

Once more, DocPath’s strive for continuous improvement by meeting the main needs of its Clients with its advanced document software solutions and the vast experience of its R&D team have led to a flexible and effective document solution that is ideal for any type of organization.

DocPath is a leading document software manufacturer that provides its world-wide customers the technology that allows them to implement of sophisticated Customer Communications Management and Document Output Management processes. Created in 1992, DocPath’s solutions are found in companies all over the world. Among its international clients are prestigious banks and first class corporations, which are aided by DocPath solutions by simplifying the complicated and critical task involving the design and distribution of business and customer documents. DocPath maintains a strong commitment to R&D&i, an area that receives a good amount of its revenue, and in which lies the key to the company´s success.

For more information, visit: www.docpath.com.

Disclaimer: DocPath and the DocPath logo are DocPath Corp. registered trademarks. All rights reserved. Other mentioned trademarks may be property of their respective owners.

About DocPath Corp.

DocPath is a leading provider of document software geared towards Costumer Communications Management (CCM) and Document Output Management (DOM).

DocPath Corp.
3360 Martin Farm Road
Suwanee, GA 30024
United States
+1 (678) 714 3400
communications@docpath.com
http://docpath.com/

SOURCE: DocPath Corp.

ReleaseID: 440583

NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of LendingClub Corporation (“LendingClub”) (NYSE: LC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with the Initial Public Offering on or about December 11, 2014 or who purchased shares from December 11, 2014 through May 6, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to: http://www.zlk.com/pslra/lendingclub or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) LendingClub’s internal controls were inadequate to ensure that LendingClub’s loans conformed to its customers’ criteria; (2) LendingClub’s internal controls were inadequate to ensure that relevant interests in third-party transactions were fully and timely disclosed; and (3) as a result, LendingClub’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you suffered a loss in LendingClub you have until July 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 440588

Centric Health Corporation to Present at the LD Micro Invitational in Los Angeles

LOS ANGELES, CA / ACCESSWIRE / May 31, 2016 / Centric Health Corporation (“Centric Health” or “the Company”) (TSX: CHH), today announced that it will be participating in the 6th Annual LD Micro Invitational on Tuesday, June 7, 2016 at 3:00 PM PST / 6:00 PM EST. David Cutler, President and Chief Executive Officer of Centric Health, will be presenting and available to meet with investors on June 7th and 8th.

Centric Health is Canada’s leading diversified healthcare services company. It is uniquely positioned to complement the Canadian healthcare system during a period of unprecedented challenges as the Canadian seniors population is forecast to double over the coming decades. In addition, consumption will drive higher costs and result in increased wait times combined with constrained access.

Centric Health is poised for sustainable long-term growth and free cash flow generation through its leading market positions and large national networks with significant capacity and operating leverage, which allows the Company to generate high margins on incremental volumes. The Company is operating via two business divisions:

• Institutional Pharmacy Services (Specialty Pharmacy):
• one of Canada’s largest providers to seniors care communities
• Surgical and Medical Centres:
• the largest and best regarded independent surgical network in Canada.

A webcast of the presentation will be available at http://wsw.com/webcast/ldmicro10/chh.to. The webcast will be archived for one year.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

View the Company’s profile here: http://www.ldmicro.com/profile/CHH.TO

Profiles powered by LD Micro – News Compliments of Accesswire

About Centric Health

Centric Health’s vision is to be Canada’s most respected provider and brand in the independent healthcare sectors in which it operates, world renowned for delivering the highest levels of quality care and outcomes, innovative solutions and value to patients, clients and stakeholders. To this end, Centric Health primarily focuses on two core healthcare businesses:

 

• The Specialty Pharmacy division is composed of a growing national network of fulfilment centres that offer high-volume solutions for the cost effective supply of chronic medication and other specialty clinical services, serving more than 25,000 residents in over 300 seniors communities (long term care facilities, retirement homes and assisted living facilities) nationally. The Specialty Pharmacy division also provides pharmaceutical dispensing services for employees insured by corporate health plans.
• The Surgical & Medical Centres division is Canada’s largest independent surgical provider operating six facilities across four provinces. It serves a diversified customer base with private paid non-insured surgeries and diagnostics, government outsourcing of insured surgeries and diagnostics and other procedures funded by third-party payors (including Workers Compensation) and is the proud owner of Canada’s first Centre of Excellence in Metabolic and Bariatric Surgery.

With national networks of facilities in each of its businesses, deep knowledge and experience of healthcare delivery and extensive, trusted relationships with payers, physicians, and government agencies, the Company is uniquely positioned to address current and future healthcare needs in growing markets as the Canadian healthcare industry continues to evolve over the medium to long term.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

For information, please contact:

David Cutler
Chief Executive Officer
Centric Health Corporation
416-619-9401
david.cutler@centrichealth.ca

Lawrence Chamberlain
Investor Relations
NATIONAL Equicom
416-848-1457
lchamberlain@national.ca

SOURCE: Centric Health Corporation via LD Micro

ReleaseID: 440587